> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Orbital organoids reach IND: 40 days in microgravity changed a cancer drug's path - URL: https://nexi.fund/axiom-space-orbital-organoids-2026/ - Published: 2026-10-06T09:00:56.000Z - Updated: 2026-10-06T09:00:56.000Z - Description: Patient-derived glioblastoma cultures spent 40 days on the ISS and returned more uniform than the ground controls. The drug that followed, rebecsinib, sits under an active IND. Auxilium printed a kidney and a liver in orbit; Crew-13 delivered tissue hardware on October 1. - Author: Nexi.fund Labs - Tags: Space & Expansion, #mode-5, #hook-question, #track-F What happens to a tumour when you take gravity away? Forty days aboard the International Space Station produced a partial answer, published in March 2026\. Patient-derived glioblastoma cultures grown in orbit came back with more uniform morphology than the matched ground controls. Beside that result sat a second one: microgravity raised the activity of cancer drivers such as ADAR1, the enzyme targeted by a drug now in a phase 1 trial. ``` TIMELINE: Orbital biomanufacturing ─────────────────────────────────────────────────────────────────────── 2023 ───── 2024 ───── 2026-03 ───── 2026-06/07 ──── ◉ NOW ──── 2027 💊 🧫 📄 🖨️ 🧬 🚀 Ax-2: Ax-3 40-day First kidney Crew-13 Ax-5 first repeat GBM and liver stem-cell window, cancer organoid organoid bioprinted tissues ESA MOU drugs tests paper; in orbit; produced signed on orbit ADAR1 link announced in orbit Sep 10 ─────────────────────────────────────────────────────────────────────── Sources: Axiom Space · bioRxiv (Mar 2026) · Reuters (Jul 9, 2026) · NASA (Oct 1, 2026) · ESA–Axiom (Sep 10, 2026) ``` Compiled from Axiom Space mission releases, the March 2026 bioRxiv preprint, Reuters reporting from ASCEND 2026 and NASA flight notes. ## The organoid that changed the read-out Axiom Space has flown Catriona Jamieson's experiments twice. Ax-2 carried the first cancer-drug tests ever performed off Earth in 2023\. Ax-3 repeated the run a year later. Both sit inside ISSCOR, a NASA-funded centre built to keep stem cell research continuous on the station rather than tied to single payloads. The molecule that came out of it is rebecsinib. It inhibits ADAR1, an RNA-editing enzyme. In the March 2026 preprint, ADAR1 activity showed up as one of the things microgravity turns up, which makes low Earth orbit a testing platform for the inhibitor itself. Aspera Biomedicines developed the compound; Jamieson's group at the University of California, San Diego, runs the programme. Axiom's release states the regulatory position without decoration: the FDA cleared it into clinical trials under an active IND, after orbital tests on Ax-2 and Ax-3. That sentence is the milestone. An orbital experiment feeding a drug into human trials has a paper trail a regulator can point at. The engineering detail sits in the growth numbers. Aerospace America's report from the ASCEND 2026 in-space manufacturing session put orbital organoid development at two to three times the pace of matched ground controls. Two to three times is the whole argument. A screen that absorbs a quarter on Earth compresses to weeks. None of it produces an organ for a patient. The deliverable is a read-out: denser, faster tissue that tells a programme whether to spend the next $50 million. 🎯 **Three conclusions** The output is regulatory. Rebecsinib holds active IND status after orbital tests on Ax-2 and Ax-3 — an experiment-to-filing trail, not a demonstration. The return is throughput. Orbital organoids run 2–3× the pace of ground controls, which is why the near-term business is screening, not transplantable tissue. The capability is bolted to flight cadence. Every programme above depends on a launch window, and the ISS retires under NASA's 2030 plan. ## Printing joined the same manifest Auxilium Biotechnologies put its kidney and liver structures through bioprinting in orbit; the samples returned on SpaceX's CRS-34 splashdown on June 17, 2026, with results released July 9\. NASA's Expedition 75 crew ran cartilage bioprinting on the station in mid-September. On October 1, SpaceX launched Crew-13 carrying hardware for stem-cell-derived tissue production, which NASA frames around disease modelling and drug testing. 2–3× vs ground controls #### Orbital organoid growth rate Patient-derived tumour organoids developed two to three times faster in low Earth orbit than in matched ground incubators. · *Aerospace America, ASCEND 2026* Three programmes, three tissue types, one dependency: flight slots. A printer that runs once per resupply cycle cannot serve a pipeline that wants monthly screens. Cadence, not printer resolution, sets the ceiling. Watch for that distinction in company language. Auxilium sells a manufacturing claim. NASA sells a research claim. Axiom sells access. All three are renting the same rack space. ## Who owns the rack space Follow the manifests and four roles separate cleanly. Axiom Space sells crew seats and lab volume; its memorandum of understanding with ESA on September 10 is a demand signal from a space agency, which reads differently from a startup pilot. Starlab and Vast sell pressurised volume for the period after the ISS. Auxilium and BioOrbit sell the instruments that ride inside: printers, culture hardware, consumables that make a payload repeatable instead of a one-off. Redwire and the ISS National Lab sell the integration step that turns a proposal into a manifested slot. ISS National Lab channels part of that work through its Orbital Edge Accelerator, aimed at companies building hardware for the orbital economy. BioOrbit's £9.8 million seed round funds the same equipment category from the other direction: culture systems designed for microgravity rather than adapted from a ground incubator. The distinction matters when a programme drafts a 2027 budget. Seats and volume are booked years out. Instruments can be bought this year. A team that secures hardware without a slot owns an expensive paperweight; a team that books a slot without hardware waits for the next resupply. ## The line item the ISS retires with Hardware is the visible part of the transition. Axiom signed a memorandum of understanding with ESA on September 10, 2026 to widen European access to low Earth orbit, and its Ax-5 mission was selected on January 30, 2026 for a 2027 flight. Starlab and Vast are building stations. BioOrbit closed a £9.8 million seed round to industrialise cell culture hardware. Varda and United Therapeutics, Redwire and ExesaLibero have already paired payload makers with commercial platforms. The question for a biotech programme budgeting 2027 work is narrow. Which station carries the assay, at what flight rate, under whose data package? #### What still has to be true **Flight cadence holds.** A screen worth running monthly needs four to six windows a year, not one. **Regulators accept orbital read-outs repeatedly.** One molecule cleared under an active IND after Ax-2 and Ax-3 tests is a precedent. A second one is a pattern. **Cost per sample beats the counter.** Two to three times faster loses to ten times more expensive. ISS National Lab channels money through its Orbital Edge Accelerator to answer exactly those three. If the answers arrive before the station's retirement date, orbital screening leaves as a service. If they arrive after, the work restarts on Starlab or Axiom Station with fresh qualification. ## Where the pipeline sits today One IND. Two bioprinted organ types returned to Earth. Crew-13 delivering tissue production hardware in October. The chain runs from microgravity observation to a filing regulators signed. Ax-5 flies in 2027\. If Jamieson's organoids ride it, the orbital screen becomes a repeat service with a schedule. If not, the 2026 results stay a pair of experiments that happened to share a rack. [ Glioblastoma–myeloid organoids cultured 40 days in microgravity The March 2026 preprint behind the uniformity result and the ADAR1 finding, including the link to a phase 1 inhibitor. bioRxiv ](https://www.biorxiv.org/content/10.64898/2026.03.06.710192v1.full.pdf?ref=nexi.fund) Primary evidence for the 40-day culture result — the number every other claim in this piece leans on. [ First space-tested Aspera Biomedicines drug advances toward clinical trials Axiom Space's own account of rebecsinib moving under an active IND after testing on Ax-2 and Ax-3. Axiom Space ](https://www.axiomspace.com/release/cancer-research-rebecsinib?ref=nexi.fund) Company primary source for the regulatory status — worth reading against the preprint for where the two accounts diverge. [ From the lab to low Earth orbit: in-space manufacturers chart the industrial path Trade reporting from the ASCEND 2026 session where the two-to-three-times growth rate and the manufacturing roadmap were presented. Aerospace America (AIAA) ](https://aerospaceamerica.aiaa.org/institute/from-the-lab-to-low-earth-orbit-part-1-in-space-manufacturers-chart-the-path-to-an-industrial-future?ref=nexi.fund) Independent confirmation of the throughput numbers from outside the companies selling the capacity.